PMID- 12390293
OWN - NLM
STAT- MEDLINE
DCOM- 20030422
LR  - 20190826
IS  - 0305-1870 (Print)
IS  - 0305-1870 (Linking)
VI  - 29
IP  - 12
DP  - 2002 Dec
TI  - Effects of the angiotensin-converting enzyme inhibitor alacepril on exercise 
      capacity and neurohormonal factors in patients with mild-to-moderate heart 
      failure.
PG  - 1060-5
AB  - 1. Alacepril is a long-acting, sulphydryl-containing angiotensin-converting 
      enzyme inhibitor. Data are limited regarding the effects of alacepril on exercise 
      tolerance in patients with chronic heart failure (CHF). The aim of the present 
      study was to determine the effects of chronic alacepril treatment on exercise 
      capacity and neurohormones in patients with CHF. 2. The effects of 12 weeks 
      treatment with alacepril on clinical, echocardiographic and cardiopulmonary 
      exercise variables were studied in 18 CHF patients (mean age: 63 +/- 2 years; New 
      York Heart Association (NYHA) class I n = 6, class II n = 10, class III n = 2) in 
      a cross-over fashion. Resting levels of plasma noradrenaline, renin-angiotensin 
      system activity and natriuretic peptides were evaluated. 3. Treatment with 
      alacepril significantly improved NYHA functional class and decreased 
      cardiothoracic ratio (60.1 +/- 2.0 vs 58.1 +/- 1.9% for baseline vs alacepril, 
      respectively; P < 0.01). Cardiac dimensions by echocardiogram were decreased 
      after alacepril therapy. Peak Vo2 (17.7 +/- 1.2 vs 19.5 +/- 1.3 mL/min per kg; P 
      < 0.01) and anaerobic threshold (11.7 +/- 0.6 vs 13.2 +/- 0.9 mL/min per kg; P < 
      0.01) increased with alacepril treatment. Plasma noradrenaline and plasma 
      angiotensin II levels were not altered, but plasma aldosterone (77.7 +/- 13.5 vs 
      51.7 +/- 9.7 pg/mL; P < 0.01), atrial natriuretic peptide (ANP; 86.5 +/- 20.3 vs 
      43.6 +/- 7.6 pg/mL; P < 0.05) and brain natriuretic peptide (BNP; 222.7 +/- 59.3 
      vs 117.7 +/- 34.3 pg/mL; P < 0.05) levels decreased after alacepril treatment. 4. 
      These results suggest that treatment with alacepril improves functional status 
      and exercise capacity in patients with mild-to-moderate CHF. Neurohormones were 
      favourably influenced by alacepril therapy, with significant decreases in plasma 
      aldosterone, ANP and BNP levels.
FAU - Kinugawa, Toru
AU  - Kinugawa T
AD  - First Department of Internal Medicine, Tottori University Faculty of Medicine, 
      Yonago, Japan. kinugawa@grape.med.tottori-u.ac.jp
FAU - Osaki, Shuichi
AU  - Osaki S
FAU - Kato, Masahiko
AU  - Kato M
FAU - Ogino, Kazuhide
AU  - Ogino K
FAU - Shimoyama, Masaki
AU  - Shimoyama M
FAU - Tomikura, Yoko
AU  - Tomikura Y
FAU - Igawa, Osamu
AU  - Igawa O
FAU - Hisatome, Ichiro
AU  - Hisatome I
FAU - Shigemasa, Chiaki
AU  - Shigemasa C
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Neurotransmitter Agents)
RN  - 9G64RSX1XD (Captopril)
RN  - X39TL7JDPF (alacepril)
SB  - IM
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/*pharmacology/therapeutic use
MH  - Captopril/*analogs & derivatives/*pharmacology/therapeutic use
MH  - Cross-Over Studies
MH  - Exercise Test/*drug effects/statistics & numerical data
MH  - Female
MH  - Heart Failure/*blood/drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neurotransmitter Agents/*blood
MH  - Patients/statistics & numerical data
MH  - Statistics, Nonparametric
EDAT- 2002/10/23 04:00
MHDA- 2003/04/23 05:00
CRDT- 2002/10/23 04:00
PHST- 2002/10/23 04:00 [pubmed]
PHST- 2003/04/23 05:00 [medline]
PHST- 2002/10/23 04:00 [entrez]
AID - 3779 [pii]
AID - 10.1046/j.1440-1681.2002.03779.x [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2002 Dec;29(12):1060-5. doi: 
      10.1046/j.1440-1681.2002.03779.x.